Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsChris Brinzey - PartnerRobin Harper Cowie - CFOScott Hutton - CEOWilliam Ruby - Equity Research AssociateConference Call ParticipantsAndrew Brackmann - Equity Research AnalystJohn Wilkin - Equity Research Analyst of Diagnostics and Life Science ToolsKyle Mikson - Managing Director and Senior Research AnalystThomas Flaten - Senior Research AnalystOperatorStanding by. Welcome to the Biodesix 4th quarter 2025 earni ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsChris Brinzey - PartnerRobin Harper Cowie - CFOScott Hutton - CEOWilliam Ruby - Equity Research AssociateConference Call ParticipantsAndrew Brackmann - Equity Research AnalystJohn Wilkin - Equity Research Analyst of Diagnostics and Life Science ToolsKyle Mikson - Managing Director and Senior Research AnalystThomas Flaten - Senior Research AnalystOperatorStanding by. Welcome to the Biodesix fourth quarter 2025 ea ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker4Standing by. Welcome to the Biodesix 4th quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 agai ...

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $21.8 million, representing a 20% increase year-over-year [17] - Gross margin improved by 400 basis points to 81% compared to 77% in Q3 2024 [19] - Adjusted EBITDA loss improved by 18% year-over-year to a loss of $4.6 million [21] Business Line Data and Key Metrics Changes - Lung diagnostic testing revenue was $19.8 million from approximately 15,700 tests, a 16% increase in revenue and 13% growth in test volumes compared to Q3 2024 [18] - Development services revenue grew 97% year-over-year to $1.9 million, with $12.9 million under contract, marking a 16% increase [14][19] Market Data and Key Metrics Changes - The company expanded its access to the lung nodule market, increasing the percentage of Nodify tests ordered from primary care from 4% to 11% in September 2025 [7] - Digital test ordering capabilities increased by 43% over the previous year [10] Company Strategy and Development Direction - The company is focused on three main goals: growing top-line revenue, improving operational effectiveness, and advancing its product pipeline [4] - A three-tiered commercial strategy has been implemented to enhance lung nodule management and increase growth potential [5] - The company is leveraging partnerships with Bio-Rad Laboratories and Thermo Fisher Scientific to expand its product development pipeline [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EBITDA positivity in Q4 2025, supported by strong revenue growth and improved gross margins [22][37] - The company is increasing its revenue guidance for 2025 to a range of $84-$86 million based on current momentum [17] Other Important Information - The company presented interim data from the Clarify study at the CHEST annual meeting, reinforcing the clinical utility of Nodify testing [11][12] - The company is actively working to resolve administrative barriers with Medicare Advantage plans, which contributed to revenue growth [18] Q&A Session Summary Question: Can you discuss the signals that your primary care expansion is working? - Management highlighted that initial proof points come from pulmonologists introducing the company to their referral networks, leading to increased adoption and earlier diagnosis [25][26] Question: What can investors expect regarding product portfolio expansion into 2026? - Management indicated that an R&D event will provide updates on ongoing efforts and pipeline developments, emphasizing the importance of partnerships [28][29] Question: What is the ramp-up plan for the new sales reps and expected productivity? - Management noted a consistent ramp-up in sales rep productivity, aiming for $1 million per sales rep at full productivity [31][32] Question: How confident is the company in achieving adjusted EBITDA positivity in Q4? - Management expressed strong confidence in reaching adjusted EBITDA positivity based on Q3 performance and momentum into Q4 [36][37]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $20 million, representing a 12% increase year over year [18] - Gross margin improved to 80%, up 150 basis points from 78.4% in Q2 2024 [19] - Net loss for Q2 2025 was $11.5 million, an increase of 6% year over year [20] - Adjusted EBITDA loss was $7.2 million, which is a 29% increase year over year [20] - Cash used from operations improved by 23% to $6.6 million compared to $8.6 million in Q2 2024 [20] Business Line Data and Key Metrics Changes - Lung diagnostic testing revenue was $17.9 million from approximately 15,100 tests, compared to $16.5 million from approximately 13,900 tests in Q2 2024, representing 9% growth in test volumes and 8% growth in revenue [18] - Development services revenue grew by 53% year over year to $2.1 million [18][16] Market Data and Key Metrics Changes - The company ended Q2 2025 with $12.5 million under contract for development services, marking a 54% increase year over year and an all-time high [18][16] - The average number of sales representatives in the field was 74, with plans to increase to 83-87 in Q3 and 93-97 in Q4 [10][21] Company Strategy and Development Direction - The company aims to grow top-line revenue, improve operational effectiveness, and achieve positive adjusted EBITDA by Q4 2025 [5] - A territory-based sales strategy was implemented to engage pulmonologists and their referral networks, addressing nearly 50% of patients with lung nodules managed by primary care [7][6] - The company is focused on expanding its clinical evidence base and pipeline, with multiple presentations at key conferences [12][13][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the primary care strategy, noting that feedback from pulmonologists supports the approach [30] - The company anticipates continued growth in the development services segment, particularly in Q4 due to pharmaceutical budget cycles [45] - Management remains optimistic about achieving adjusted EBITDA positivity in Q4 2025, driven primarily by revenue growth [21][40] Other Important Information - The company has made significant progress in clinical studies, including the ALPITUDE study, which has reached patient enrollment requirements [23][12] - The company was recognized as a top workplace for the second consecutive year, reflecting its strong culture and team [24] Q&A Session Summary Question: Can you unpack the primary care opportunity and your confidence in the strategy? - Management indicated that confidence has increased due to broader experiences and consistent feedback from pulmonologists [30][29] Question: What trends are seen in electronic ordering utilization? - Management noted that electronic ordering has improved compliance and reduced test cancellations, enhancing efficiency [36][35] Question: How will the company bridge to EBITDA positivity in Q4? - The primary driver will be revenue growth from an increased number of sales representatives, with no major cost-cutting measures planned [40][42] Question: What is the outlook for development services revenue? - Management expects an uptick in Q4 due to the typical cadence of pharmaceutical companies' budgeting [45] Question: What is the growth outlook for primary care orders? - Management stated that while primary care orders have increased significantly, forecasting the exact mix with pulmonology is challenging [60][59] Question: What are the capital needs over the next year and a half? - Management is focused on achieving both adjusted EBITDA and cash flow breakeven with existing plans [71] Question: How confident is the company in maintaining $1 million per rep productivity? - Management expressed confidence based on pilot program results, indicating potential for higher productivity in some territories [73][75]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $18 million, representing a 21% increase year over year [22] - Lung diagnostic testing revenue was $16.3 million, reflecting an 18% growth, with test volumes increasing by 16% [22][24] - Gross margin improved to 79.4%, up from 78.6% in Q1 2024 [23] - Net loss for Q1 2025 was $11.1 million, an 18% improvement year over year [24] - Adjusted EBITDA loss was $6.2 million, an 11% improvement year over year [24] Business Line Data and Key Metrics Changes - Lung diagnostics revenue grew by 18%, marking the sixteenth consecutive quarter of over 15% year-over-year growth [5] - Development services revenue reached $1.7 million, a 61% increase compared to Q1 2024 [20] - The pipeline for development services ended Q1 with $10.9 million under contract, a 21% increase year over year [23] Market Data and Key Metrics Changes - The company is focusing on expanding its presence in the primary care market, which is expected to enhance patient access to lung diagnostics [9][12] - Digital test ordering increased by 58% over the last year, with customer retention for digital ordering being 40% higher than for non-digital ordering [8] Company Strategy and Development Direction - The company aims to achieve positive adjusted EBITDA by Q4 2025 while focusing on revenue growth and operational efficiencies [4][26] - A shift to a territory-based sales approach has been implemented to enhance market penetration in both pulmonology and primary care [9][11] - The company is exploring the integration of AI and radiomics into its diagnostic offerings to improve clinical workflows [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EBITDA positivity in Q4 2025 despite current challenges in the sales force expansion [24][44] - The company is optimistic about the growth potential in the primary care market, supported by positive feedback from pulmonologists [42][61] - Management acknowledged the need for careful monitoring of expenses while ramping up the sales team to meet growth targets [78] Other Important Information - The company has been recognized as a top workplace for the second consecutive year in 2025, highlighting its strong team culture [28] - The company plans to hold an R&D day in the fall to provide further insights into its pipeline and progress [20] Q&A Session Summary Question: Can you elaborate on the sales force changes and hiring challenges? - Management noted that the shift to primary care required a different hiring profile, which took longer than anticipated to finalize [32][34] Question: What is the outlook for Q2 and the rest of the year? - Management expects to have 70 to 75 sales reps in Q2, with plans to increase to 85 in Q3 and 95 in Q4 [39] Question: How are primary care physicians responding to the technology? - Early feedback indicates that primary care physicians are aware of the patient population and are interested in utilizing the diagnostic tests [41][61] Question: What is the impact of the $10 million loan on capital needs? - The additional capital provides more flexibility and confidence in achieving breakeven while supporting commercial expansion and pipeline activities [44][45] Question: How does the sales force configuration affect territory management? - Each territory will have a pulmonology sales consultant, with associate sales consultants supporting them based on specific needs and test volumes [92][93]